Open Access<p>Direct-Acting Antiviral Drugs and Occurrence of Hepatocellular Carcinoma: Unjust or Oppressed</p>
Author(s) -
Sahar M. Hassany,
Wesam Hassan,
Hani Sayed Aboalam,
Marwa Khalaf,
Amany M Nafeh,
Eman NasrEldin,
Eman Mostafa
Publication year - 2020
Publication title -
infection and drug resistance
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.033
H-Index - 39
ISSN - 1178-6973
DOI - 10.2147/idr.s241948
Subject(s) - medicine , hepatocellular carcinoma , daclatasvir , sofosbuvir , gastroenterology , hbsag , liver function , cirrhosis , ribavirin , liver disease , hepatitis c virus , hepatitis c , prospective cohort study , hepatitis b virus , immunology , virus
In interferon-free era, direct-acting antiviral agents (DAAs) have achieved high eradication rates with an excellent safety profile since revolutionized the management of hepatitis c virus (HCV) patients. Published papers have suggested a possible increased incidence of hepatocellular carcinoma (HCC) after successful DAAs treatment. Other papers have been published about the problem but without conclusive results. Because of this debate, we aim to evaluate the effects of antiviral therapy (Sofosbuvir plus Daclatasvir with or without Ribavirin) on the de novo occurrence of HCC in patients with liver cirrhosis (LC).